Fibrinogen-Like Protein 1 Is a Promising Biomarker of Psoriasis Severity and Lipid Metabolism

According to a study published in the Journal of Inflammation Research, fibrinogen-like protein 1 (FLG1) may play a role in diagnosing and staging psoriasis, psoriasis progression, and abnormal lipid metabolism.

Researchers aimed to compare the tumor necrosis factor α (TNF-α), IL-6, IL-17, IL-10, and FGL1 serum levels between patients with psoriasis and healthy control individuals. They also aimed to determine whether psoriasis complicated by abnormal lipid metabolism could be identified in a case-control study. Serum levels of TNF-α, IL-6, IL-17, IL-10, and FGL1 were analyzed in 139 untreated patients with psoriasis and 140 healthy control patients using enzyme-linked immunosorbent assays.

Patients with psoriasis had lower concentrations of serum TNF-α, IL-17, and FGL1. FGL1 was inversely correlated with high-density lipoprotein cholesterol and IL-17 in the psoriatic state. FGL1 and total cholesterol were independent determinants of the Psoriasis Area and Severity Index score in patients with psoriasis. FGL1 also identified psoriasis with abnormal lipid metabolism.

“In conclusion, serum FGL1 may be a promising biomarker for diagnosing and staging psoriasis,” concluded the study authors. “It may also be involved in its progression and comorbid abnormal lipid metabolism,” they added.

Reference
Sun X, Liu L, Chen S, et al. Fibrinogen-like protein 1 as a novel biomarker of psoriasis severity. J Inflamm Res. Published online August 15, 2022. doi:10.2147/JIR.S378953